Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2014-05-05

Clinical Trial Update: Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma [Phase 2]

View source ↗

Summary

The Phase 2 trial of sunitinib malate for East African patients with AIDS-related Kaposi sarcoma or Classic Kaposi sarcoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: AIDS-related Kaposi Sarcoma, Classic Kaposi Sarcoma | Phase 2 | Status: WITHDRAWN